$55.98
Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Overview
52-week range
$27
$59
90% of range
Avg surprise (last 3)
-52.1%
Avg reaction (last 2)
+1.5%
50% positive
Latest IV / EM
66%
EM ±10.4% · $55 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.05 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.17 | $0.23 | -26.1% | +466.7% | +16.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $2.43 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $0.17 | $0.32 | -46.9% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $0.03 | $0.18 | -83.3% | — | -13.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.04 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.28 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $240M | $205M | — | $162M | $141M | $121M | — | $84M |
| Cost of revenue | $41M | $34M | — | $28M | $19M | $16M | — | $9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $22M | $35M | — | $29M | $35M | $9M | — | $12M |
| Net income | $8M | $20M | — | $391M | $28M | $5M | — | $4M |
| EPS (diluted) | $0.05 | $0.12 | — | $2.43 | $0.17 | $0.03 | — | $0.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $483M | $442M | $79M | $74M | $129M | $132M | $180M | $196M |
| Inventory | $148M | $129M | $126M | $147M | $155M | $158M | $110M | $85M |
| Total current assets | $1.15B | $1.09B | $631M | $600M | $664M | $645M | $566M | $574M |
| Total assets | $1.64B | $1.53B | $1.06B | $1.03B | $703M | $657M | $578M | $586M |
| Long-term debt | $745M | $745M | $246M | $245M | $245M | $245M | $244M | $244M |
| Total liabilities | $1.04B | $946M | $415M | $418M | $426M | $419M | $355M | $394M |
| Total equity | $604M | $583M | $648M | $607M | $276M | $237M | $222M | $192M |